Semaglutide and empagliflozin showed comparable effectiveness in improving fatty liver disease in obese mice, both reducing inflammation, oxidative stress, and liver injury through lysophosphatidylcholine modulation.
No difference between drugs for MASLDSemaglutide and empagliflozin showed comparable effectiveness in improving fatty liver disease markers in obese mice, both modulating lysophosphatidylcholine levels
What the researchers found
In 32 mice divided into four groups (control, high-fat, semaglutide, empagliflozin), both semaglutide and empagliflozin significantly improved glycolipid metabolism, reduced inflammation and oxidative stress, and restored pathological liver structure compared to the high-fat group. No statistically significant differences were found between the two drugs for MASLD outcomes.
Metabolomics revealed that both drugs reduced levels of several lysophosphatidylcholine (LPC) species in liver tissue, suggesting the liver-protective effects may be mediated through LPC modulation.
Why it matters
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects roughly a quarter of the global population and has no approved cure. Semaglutide is already being studied in human MASLD trials, and this study reveals a potential mechanism — LPC modulation — that could explain its liver benefits and guide development of more targeted therapies.
How the study worked
32 mice were randomly assigned to four groups: control, high-fat diet, semaglutide treatment, and empagliflozin treatment. Researchers assessed body weight changes, blood sugar and lipid profiles, inflammatory and oxidative stress markers, liver histopathology, and performed metabolomics analysis to identify molecular changes associated with treatment effects.
What this study cannot tell us
This is a mouse study with a small sample size (8 per group), limiting statistical power. The high-fat diet model may not fully replicate human MASLD pathogenesis. The metabolomics findings are associative and don't prove LPC reduction is the causal mechanism. Drug doses and treatment duration were not specified in the abstract. Human studies are needed to confirm these mechanisms and the comparative effectiveness of the two drugs.
How to read the evidence
This is a preclinical mouse study with a small sample size (32 mice total, 8 per group) published in the World Journal of Hepatology. The inclusion of metabolomics adds mechanistic depth, but the findings are limited to a single animal model.
When this study was published
Published in 2025, this is a very recent study contributing to the rapidly growing evidence base for GLP-1 receptor agonists in liver disease.
The bigger picture
MASLD/MASH is becoming one of the most common liver diseases worldwide as obesity rates climb. GLP-1 receptor agonists like semaglutide are among the most promising therapies, with resmetirom being the first FDA-approved drug for MASH. Understanding that semaglutide may work through LPC modulation adds mechanistic depth and could inform combination therapy strategies.
Questions still open
- Would combining semaglutide and empagliflozin provide additive liver benefits over either drug alone in MASLD?
- Is LPC reduction a direct drug effect or a downstream consequence of weight loss and metabolic improvement?
- Do these mechanistic findings translate to the ongoing human MASLD trials of semaglutide?
Common questions
What is MASLD and how is it different from NAFLD?
What are lysophosphatidylcholines and why do they matter?
Read the original research
Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.
World journal of hepatology, 17(10), 110402
Citation
Niu, Shu; Chen, Shu-Chun; Wang, Chen-Xi; Yue, Lin; Wang, Shu-Qi. (2025). Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.. World journal of hepatology, 17(10), 110402. https://doi.org/10.4254/wjh.v17.i10.110402